Skip to main content
NASDAQ:HBIO

Harvard Bioscience Competitors

$6.95
-0.06 (-0.86 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.90
$7.03
50-Day Range
$5.39
$7.35
52-Week Range
$2.50
$7.80
Volume327,750 shs
Average Volume226,805 shs
Market Capitalization$277.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.73

Competitors

Harvard Bioscience (NASDAQ:HBIO) Vs. TMO, ILMN, A, MTD, WAT, and BIO

Should you be buying HBIO stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to Harvard Bioscience, including Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), and Bio-Rad Laboratories (BIO).

Harvard Bioscience (NASDAQ:HBIO) and Thermo Fisher Scientific (NYSE:TMO) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

64.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 87.2% of Thermo Fisher Scientific shares are held by institutional investors. 5.4% of Harvard Bioscience shares are held by insiders. Comparatively, 0.4% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Harvard Bioscience and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harvard Bioscience-6.51%4.29%2.15%
Thermo Fisher Scientific17.12%21.35%10.55%

Analyst Ratings

This is a breakdown of recent recommendations for Harvard Bioscience and Thermo Fisher Scientific, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harvard Bioscience00303.00
Thermo Fisher Scientific021802.90

Harvard Bioscience currently has a consensus target price of $9.00, indicating a potential upside of 29.50%. Thermo Fisher Scientific has a consensus target price of $536.8947, indicating a potential upside of 18.06%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Thermo Fisher Scientific.

Risk & Volatility

Harvard Bioscience has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

Earnings & Valuation

This table compares Harvard Bioscience and Thermo Fisher Scientific's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harvard Bioscience$116.18 million2.39$-4,690,000.00$0.1257.92
Thermo Fisher Scientific$25.54 billion7.00$3.70 billion$12.3536.82

Thermo Fisher Scientific has higher revenue and earnings than Harvard Bioscience. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Thermo Fisher Scientific beats Harvard Bioscience on 10 of the 14 factors compared between the two stocks.

Harvard Bioscience (NASDAQ:HBIO) and Illumina (NASDAQ:ILMN) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

64.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 90.0% of Illumina shares are held by institutional investors. 5.4% of Harvard Bioscience shares are held by insiders. Comparatively, 0.4% of Illumina shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Harvard Bioscience and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harvard Bioscience-6.51%4.29%2.15%
Illumina19.70%15.93%10.09%

Analyst Ratings

This is a breakdown of recent recommendations for Harvard Bioscience and Illumina, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harvard Bioscience00303.00
Illumina47602.12

Harvard Bioscience currently has a consensus target price of $9.00, indicating a potential upside of 29.50%. Illumina has a consensus target price of $374.50, indicating a potential upside of 0.45%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Illumina.

Risk & Volatility

Harvard Bioscience has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Earnings & Valuation

This table compares Harvard Bioscience and Illumina's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harvard Bioscience$116.18 million2.39$-4,690,000.00$0.1257.92
Illumina$3.54 billion15.36$1.00 billion$6.5756.75

Illumina has higher revenue and earnings than Harvard Bioscience. Illumina is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats Harvard Bioscience on 10 of the 14 factors compared between the two stocks.

Harvard Bioscience (NASDAQ:HBIO) and Agilent Technologies (NYSE:A) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

64.9% of Harvard Bioscience shares are held by institutional investors. 5.4% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Harvard Bioscience and Agilent Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harvard Bioscience-6.51%4.29%2.15%
Agilent Technologies13.47%21.02%10.73%

Analyst Ratings

This is a breakdown of recent recommendations for Harvard Bioscience and Agilent Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harvard Bioscience00303.00
Agilent Technologies061902.76

Harvard Bioscience currently has a consensus target price of $9.00, indicating a potential upside of 29.50%. Agilent Technologies has a consensus target price of $107.4350, indicating a potential downside of 16.48%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Agilent Technologies.

Risk & Volatility

Harvard Bioscience has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Earnings & Valuation

This table compares Harvard Bioscience and Agilent Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harvard Bioscience$116.18 million2.39$-4,690,000.00$0.1257.92
Agilent Technologies$5.34 billion7.34$719 million$3.2839.22

Agilent Technologies has higher revenue and earnings than Harvard Bioscience. Agilent Technologies is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Agilent Technologies beats Harvard Bioscience on 9 of the 14 factors compared between the two stocks.

Harvard Bioscience (NASDAQ:HBIO) and Mettler-Toledo International (NYSE:MTD) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

64.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 93.2% of Mettler-Toledo International shares are held by institutional investors. 5.4% of Harvard Bioscience shares are held by insiders. Comparatively, 3.2% of Mettler-Toledo International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Harvard Bioscience and Mettler-Toledo International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harvard Bioscience-6.51%4.29%2.15%
Mettler-Toledo International19.36%144.89%21.11%

Analyst Ratings

This is a breakdown of recent recommendations for Harvard Bioscience and Mettler-Toledo International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harvard Bioscience00303.00
Mettler-Toledo International23101.83

Harvard Bioscience currently has a consensus target price of $9.00, indicating a potential upside of 29.50%. Mettler-Toledo International has a consensus target price of $1,048.3333, indicating a potential downside of 15.56%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Mettler-Toledo International.

Risk & Volatility

Harvard Bioscience has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Earnings & Valuation

This table compares Harvard Bioscience and Mettler-Toledo International's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harvard Bioscience$116.18 million2.39$-4,690,000.00$0.1257.92
Mettler-Toledo International$3.01 billion9.60$561.11 million$22.7754.52

Mettler-Toledo International has higher revenue and earnings than Harvard Bioscience. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Mettler-Toledo International beats Harvard Bioscience on 9 of the 14 factors compared between the two stocks.

Harvard Bioscience (NASDAQ:HBIO) and Waters (NYSE:WAT) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

64.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 91.8% of Waters shares are held by institutional investors. 5.4% of Harvard Bioscience shares are held by insiders. Comparatively, 1.5% of Waters shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Harvard Bioscience and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harvard Bioscience-6.51%4.29%2.15%
Waters22.61%-349.31%21.11%

Analyst Ratings

This is a breakdown of recent recommendations for Harvard Bioscience and Waters, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harvard Bioscience00303.00
Waters37101.82

Harvard Bioscience currently has a consensus target price of $9.00, indicating a potential upside of 29.50%. Waters has a consensus target price of $251.25, indicating a potential downside of 17.25%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Waters.

Risk & Volatility

Harvard Bioscience has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Earnings & Valuation

This table compares Harvard Bioscience and Waters' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harvard Bioscience$116.18 million2.39$-4,690,000.00$0.1257.92
Waters$2.41 billion7.78$592.20 million$8.9933.78

Waters has higher revenue and earnings than Harvard Bioscience. Waters is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Waters beats Harvard Bioscience on 8 of the 14 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Harvard Bioscience (NASDAQ:HBIO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Bio-Rad Laboratories and Harvard Bioscience, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories00303.00
Harvard Bioscience00303.00

Bio-Rad Laboratories currently has a consensus target price of $700.00, suggesting a potential upside of 19.89%. Harvard Bioscience has a consensus target price of $9.00, suggesting a potential upside of 29.50%. Given Harvard Bioscience's higher probable upside, analysts clearly believe Harvard Bioscience is more favorable than Bio-Rad Laboratories.

Earnings and Valuation

This table compares Bio-Rad Laboratories and Harvard Bioscience's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion7.52$1.76 billion$7.0682.70
Harvard Bioscience$116.18 million2.39$-4,690,000.00$0.1257.92

Bio-Rad Laboratories has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bio-Rad Laboratories and Harvard Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories147.91%3.77%2.74%
Harvard Bioscience-6.51%4.29%2.15%

Insider & Institutional Ownership

63.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 64.9% of Harvard Bioscience shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 5.4% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Bio-Rad Laboratories has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500.

Summary

Bio-Rad Laboratories beats Harvard Bioscience on 8 of the 12 factors compared between the two stocks.


Harvard Bioscience Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.3$454.78-2.0%$178.74 billion$25.54 billion37.28Insider Selling
Analyst Revision
Illumina logo
ILMN
Illumina
1.6$372.84-2.3%$54.43 billion$3.54 billion86.51
Agilent Technologies logo
A
Agilent Technologies
1.8$128.64-2.2%$39.20 billion$5.34 billion55.93
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,241.45-0.1%$28.89 billion$3.01 billion52.23Earnings Announcement
Waters logo
WAT
Waters
1.3$303.64-4.0%$18.73 billion$2.41 billion37.81Earnings Announcement
Analyst Report
Analyst Revision
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$583.89-2.1%$17.38 billion$2.31 billion5.00
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.3$316.76-1.2%$15.92 billion$2.62 billion52.79Insider Selling
High Trading Volume
Analyst Revision
Bio-Techne logo
TECH
Bio-Techne
1.8$408.88-1.6%$15.90 billion$738.69 million65.42Earnings Announcement
Dividend Announcement
PerkinElmer logo
PKI
PerkinElmer
1.9$137.86-1.1%$15.45 billion$2.88 billion37.46Analyst Revision
Bruker logo
BRKR
Bruker
1.7$66.45-4.1%$10.07 billion$2.07 billion65.15Analyst Revision
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$22.93-5.1%$4.55 billion$90.89 million-81.89Gap Down
Luminex logo
LMNX
Luminex
1.5$36.62-0.1%$1.73 billion$334.64 million93.90
Fluidigm logo
FLDM
Fluidigm
1.8$5.18-6.0%$388.31 million$117.24 million-7.73Earnings Announcement
Analyst Report
Gap Down
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.85-0.0%$61.64 million$420,000.00-1.45Upcoming Earnings
Analyst Report
News Coverage
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.